Background: Due to the lack of face-to-face trials between ACE inhibitors, clinicians and third-party funders may assume they provide similar outcomes. As a result, ACE inhibitors may be prescribed interchangeably and deemed to provide the same outcomes for all patients when used chronically, that is for more than six months. Objective: This meta-analysis aims to dispute the assumption of a class effect when prescribing ACE inhibitors (ACEIs), since the evidence from all the clinical trials is not uniform and therefore a direct comparison is impossible. Methods: Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included). The average length of ACEI exposure per trial had to be longer than six months). This meta-analysis was performed using odds ratios as the parameter of efficacy in a fixed-effects model. Results/Conclusion: Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001). Perindopril alone or as part of combination therapy in clinical trials seemed to deliver clear and consistent outcome differences compared to other ACEI trials. In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.
These guidelines therefore leave the impression that the clinical benefit across the spectrum of ACEI molecules may be taken as uniform. This leads the clinician to believe that the outcomes from an array of diverse randomised, controlled trials are the same, despite significant differences in design criteria (inclusion and exclusion criteria, dosage and dosing intervals, etc).
The aim of this meta-analysis was to compare the magnitude of clinical benefit across the spectrum of ACEI molecules, irrespective of trial design and dosage, since this is usually the way in which these products are used in clinical practice. It was therefore noted that ACEIs are prescribed in combination with other drugs to treat cardiovascular conditions in approximately 80% of patients, 4 making it illogical to try and separate the effect of combinations from that of single molecules, since the clinical benefit is the ultimate driver of how the patient should be treated.
It is well established that a broad range of blood pressurelowering drugs, including ACEIs, reduce the risks of major Any drug that lowers BP unless absolutely contraindicated, will conffer protection against target-organ damage. However, the following classes of drugs have additional protective properties in the case of the listed associated clinical conditions/target-organ damage. Chronic kidney disease ACEI or ARB -usually in combination with a diuretic Isolated systolic hypertension Low-dose thiazide or thiazide-like diuretic or long-acting CCB cardiovascular (CV) events. Various meta-regression analyses and overviews of trials have determined the benefits of blood pressure lowering. [5] [6] [7] The conclusions made in ACEI trials (i.e. ACEI vs angiotensin receptor blockers, calcium channel blockers, diuretics and β-blockers) have further emphasised the need for ACEIs to be part of standard therapy, not only for hypertension but for the majority of cardiovascular conditions. 5, 6, 8, 9 However, no formal attempts have been made to evaluate the contribution of one or more ACEIs to the specific value of the outcomes achieved by the class.
Compelling indications Drug class
This analysis focuses on the contribution of perindopril to the overall benefits seen in the ACEI class, due to the large number of positive clinical trials utilising perindopril. It has already been established that there is sufficient clinical data demonstrating the proven clinical benefit of perindopril in various cardiovascular conditions. This meta-analysis was undertaken to determine whether perindopril produces a greater reduction in cardiovascular events and/or morbidity/mortality outcomes for all patients versus all the other commonly prescribed ACEIs combined as a class. The main aim of this analysis was therefore to compare the ACEI trials that delivered tangible clinical outcomes (irrespective of type of outcome).
Applying the results of clinical trials to general practice is extremely difficult. This analysis, by pooling the clinical trial data, will allow clinicians to discern which molecule has the most robust clinical data to support its use in any patient within the cardiovascular continuum.
Methods
The following trials were considered for inclusion: all randomised, controlled trials of ACEI therapy (placebo and/or other active therapy) for any cardiovascular outcomes. A literature search was conducted using Pubmed, Medline and Cochrane library. Relevant articles were selected on the basis of titles, references cited in reviews and commentaries, and selected publications. The rationale for selection of these trials was to determine whether the ACEI arm of the trial had an effect on the clinically stated outcomes irrespective of comparator, blood pressure lowering or patient-specific characteristics. The fact that baseline criteria differed among the studies is acknowledged, however this was a drawback of all indirect comparisons. In the absence of uniformity, this analysis focuses on clinical outcomes as the driver of the comparison, since this ultimately informs clinical practice and is the only guarantee of benefit. It is therefore acknowledged that this analysis is not typical, in that the baseline demographics differ, but this is necessarily due to the lack of suitable comparable studies.
All studies of a minimum of six months' duration that measured a specific ACEI outcome effect, both composite and individual cardiovascular measures, were included in the analysis. Studies measuring only surrogate endpoints were not considered.
The qualifying studies were checked for: blinding, randomisation, completeness of follow up, and methods of measuring outcome events. All trials had to have reported at least one of the pre-specified outcomes (all-cause mortality, stroke, CV events, mortality due to CV events, and myocardial infarction) and had to have had at least six months' follow up. Due to large discrepancies in the primary outcomes, an analysis was performed using the primary outcome of the trials, irrespective of these differences, i.e. was the stated outcome reached or not? (see Fig. 1 for search strategy).
The meta-analysis was performed using odds ratios (ORs) as the parameter of efficacy, utilising a fixed-effects model. This is a measure of treatment effectiveness and also examines the effects of other variables in that relationship using logistic regression. The influence of the perindopril studies was assessed on the pooled effect sizes by excluding these studies in a manner similar to the Tobias method. 10 This measured the influence of the perinodopril studies against the combined ACEI effect using Statsdirect software.
Results
The initial literature search resulted in 253 studies, but outcome data were available for only 30 trials that met the inclusion criteria. These trials in total included approximately 204 000 patients (see Table 2 for demographic data).
Seven ACEIs were researched in the included studies, irrespective of dosages and patient characteristics. The primary endpoint of all trials differed in some respects, but the majority were composite endpoints. Composite endpoints lead to higher event rates and enable smaller sample sizes and shorter followup, or both. These endpoints may prove challenging to interpret but it is precisely this result that should be considered in making an evidence-based selection. All the primary endpoints were combined in the initial analysis. Wherever possible, especially in three-arm treatment design trials, both comparators were included in order to provide each ACEI with the maximum possible benefit of effect.
Comparison of primary endpoints
In these event-driven trials, the ACEIs as a class had a lower likelihood of an event occurring, compared to any of the comparator drugs or placebo (OR 0.91; 95% CI: 0.88-0.94; p < 0.0001). This primary endpoint analysis was only for composite endpoints. (Trials with specific primary endpoints, e.g. stroke, myocardial infarction, are analysed in that specific section.) Only four of the trials produced a statistically significant reduction in the primary Composite endpoints: a = mortality, b = fatal/non-fatal MI, c = stroke, d = hospitalisation, e = revascularisation, f = other. NS = non-significant difference in outcome. *ASCOT study stopped early due to 11% risk reduction in all-cause mortality, p = 0.0247 -safety board halted study.
AFRICA
clinical endpoint: three trials using perindopril and one using ramipril.
The effect size for perindopril alone was larger than that of the combined ACEI analysis. See Fig. 2 for details. Perindopril showed a significant risk reduction of 18% (OR 0.82; 95% CI: 0.77-0.88; p < 0.0001) when compared to the overall ACEI effect.
When this analysis was repeated, excluding the perindopril studies, the ACEI effect was reduced to 5% (OR 0.95; 95% CI: 0.91-0.98; p = 0.0039) (Fig. 3) . It is clear that the perindopril outcomes drove the magnitude of the ACEI benefit.
Myocardial infarction as outcome
In all the trials, only 18 reported an actual measure of myocardial infarction (MI) as a specific outcome. No separate analysis of fatal and non-fatal MI was performed, as most studies opted to group the two outcomes, or selected and reported on only one. A subgroup of each incident would therefore reduce the statistical power and overall impact, defying the aim of this analysis.
The perindopril trials demonstrated a highly significant event reduction (OR 0.78; 95% CI: 0.72-0.85; p < 0.0001) (Fig. 4) . This was better than the event reduction with all other ACEIs combined (OR 0.86; 95% CI: 0.80-0.91; p < 0.0001). Perindopril resulted in nearly twice as many events saved. The difference in absolute risk in effect was 0.32 for ACEIs and 1.45 for perindopril (p < 0.0001).
The only other ACEI that has demonstrated a benefit in reduction of MI is ramipril, as used in the HOPE trial. 19 This reduction was similar in magnitude to the perindopril effect but has only been proven in high-risk CAD patients.
Stroke as outcome
This current analysis confirms previous results, 5, 39 in that when the ACEIs were pooled, the overall effect resulted in a risk reduction (OR 0.96; p = 0.0451). The effect of perindopril on stroke demonstrated a highly significant reduction in event rate (OR 0.79; 95% CI: 0.72-0.86; p < 0.0001). However, the exclusion of perindopril trials from the other ACEI trials reproduced a nonsignificant reduction in stroke events (OR 1.05; p = 0.1287) (Fig.  5 compared to comparator drugs) .
In pooling all the evidence for stroke reductions with ACEIs, the effect of perindopril became diluted. Therefore, from the data set analysed, all ACEIs cannot be advocated to reduce the risk of stroke. This reconfirms findings that lowering blood pressure is important but that the particular drug properties and dosages may be even more relevant.
Mortality as outcome
Mortality is the most commonly measured outcome in cardiovascular trials (and probably the most critical), although in many instances the causes for death are not analysed homogeneously. In order to produce an objective, meaningful analysis, all causes of mortality were combined; there was no separation of CV death, death due to stroke or MI, or all-cause mortality. It is well accepted that additional risk factors and co-morbid diseases may compound the measurement of this outcome, but for the patient, it remains immaterial and yet critically important. This should also be true for the treating clinician.
Perindopril, in the six outcome trials, showed a reduction in death compared to other drugs and or placebo (OR = 0.89; 95% CI: 0.84-0.95; p = 0.0008) (Fig. 6 ). This represents a significant 11% reduction in mortality, which is both a clinically and statistically significant benefit for all cardiovascular patients. This outcome includes all patients, irrespective of entry criteria (i.e. diabetes, cerebrovascular incident, hypertension, post-myocardial infarction or high risk for cardiovascular disease based on a combination of risk factors).
The ACEI benefit, demonstrated in 23 different ACEI trials, excluding perindopril, was only 5% (OR 0.95; 95% CI: 0.92-0.98; p = 0.0033). The absolute risk difference correlates to a NNT of 210 for ACEIs versus 127 for perindopril (p < 0.0001).
discussion
Only two other analyses have been performed to compare ACEI effects as a class of drugs. 40, 41 Both these articles by Pilote used ramipril as the comparator and Canadian retrospective data. The conclusions drawn indicated that survival benefits 'differed according to specific ACE inhibitor prescribed'.
In this meta-analysis of patients (n = 204 000) treated with ACEIs for different conditions in the cardiovascular continuum, the results clearly demonstrated a significant reduction in events: all-cause events (primary endpoints), mortality, stroke and myocardial infarction. According to this analysis of published clinical data, it would seem that the effects of perindopril were, however, larger than those of the rest of the class of ACEIs. The magnitude of this effect should be quantified in subsequent analyses.
It is accepted that there are differences in outcomes that may be related to the differences in baseline risk and the use of concomitant secondary medications such as statins, β-blockers and aspirin. Consideration is given to differences in design, for example, the ALLHAT study where no diuretic could be added to the ACEI. It is statistically impossible to discern individual drug effects within a trial; this does not imply a lack of effect nor does it indicate probable effect. These factors were not compensated for in this analysis due to the complexity of the multiple trial designs and the lack of comparable data. This does not detract from the outcome since the ACEI benefit was obvious in spite of the other drugs being used in all arms of the trials included, i.e. best-alternative care, and only strengthens the benefit observed with the ACEI. Clinicians are left with a clinical decision to select a drug from a class and should select based on proven outcome benefit rather than 'presumed' benefit.
In the face of conclusive evidence, science dictates that positive outcomes should be considered. The inference of outcomes between two drugs within the same class is not ideal; however in the absence of head-to-head trials, a level of informal comparison must be made. The obvious ideal solution to the dilemma of 'class effect' is a head-to-head study with comparable doses driving similar surrogate targets (e.g. blood pressure lowering) with sufficient patient numbers, but the realisation is that this will never occur within the ACEI class, mainly due to the cost implications involved.
It is more critical to view the results of multiple trials with relevant agents as being in some way attributable to the individual properties of the ACEIs, despite there being no obvious proven relationship between the pharmacological properties (e.g. half life, tissue affinity and lipophilicity) of the individual medications and their clinical benefit in the trials. The difference in the magnitude of positive outcomes achieved with specific agents compels us to appreciate these pharmacological differences and argues against a class effect.
Several recent publications have attempted to analyse the ACEI properties. The latest by Comini concluded: 'Our findings provide further proof of differential effects associated with ACE inhibitor therapy and suggest that the clinical benefits associated with these drugs may not solely reflect a class effect extending their benefit beyond blood pressure lowering effect'. 42 The findings from the current analyses are complemented by various other published analyses such as Pilote, 40 who found: 'In summary, our results suggest that not all drugs within the class of ACE inhibitors should be considered to have the same effect. The exact mechanisms causing these differences are unclear, although they are probably related to the structural and pharmacological characteristics of the individual drugs'.
Meta-analyses provide a framework to formally evaluate the treatment effect quantitatively from at least two trials. However, the Committee for Proprietary Medicinal Products guidance document on meta-analyses states that a meta-analysis involving trials that are not convincing in their own right is inferior to one robust trial supported by smaller trials. From a statistical point of view, it is important to evaluate the possibility of a qualitative trial-by-treatment interaction, and to be aware that differential exposure to study medication across different trials can have an AFRICA effect on outcome. 43 This clearly confirms that all the perindopril trials with robust clinical outcomes should be considered to be more valuable than the other ACEI trials with less-than-convincing outcomes.
In order to make any meaningful comparison of drug usage, the doses of the ACEIs need to be considered. It is evident that in many trials, the positive outcomes were only achieved when high dosages of ACEIs were used. This was confirmed by the high-dose ramipril in high-risk patients in the HOPE study. Also, when using enalapril or lisinopril, the only doses with confirmed outcomes were in excess of 40 mg (SOLVD I, 32 CONSENSUS I 30 studies). Perindopril's outcomes were achieved over the entire dose spectrum, depending on the specific outcome tested (4-8 mg). 7, [11] [12] [13] [14] 28 However, when outcomes were positive in the high-risk patients, the dosage of perindopril used was also at the top end of the dose range (EUROPA 12 ) (8 mg). This is re-emphasised in the ADVANCE study, 7 where 50% of patients were on 4 mg perindopril and 50% on 8 mg perindopril. ADVANCE measured the effect of high-dose perindopril in reducing outcomes.
Comparable outcomes with most commonly used ACEIs: enalapril and lisinopril
The results of the meta-analysis isolating the enalapril and lisinopril results are summarised in Table 3 . Comparing perindopril with enalapril/lisinopril, the magnitude of benefit is obvious: MI reduction was the only significant outcome for enalapril/lisinopril, which translates into an ARR of 0.40* versus absolute risk reduction (ARR) or 1.45 for perindopril. This means that to reduce one event, 250 patients need treatment with enalapril/lisinopril versus only 69 with perindopril. (*Calculated from data obtained from STOP2, ALLHAT, ANBP2, ABCD and CAMELOT studies.)
The other outcomes for enalapril/lisinopril were not significant, whereas perindopril maintained the same order of benefit (NNT: 60, 63, 124, respectively for composite outcome, stroke, and mortality**). Since the cost of a single event is generally high, this clearly offsets any price difference between drugs. (**Calculated from data obtained from ASCOT, EUROPA and PROGRESS studies.) The absolute differences between perindopril and enalapril/lisinopril translate into a two-to three-fold reduction in outcomes.
Similarly, ramipril effects should be considered in their entirety with DREAM, DIABHYCAR, PART-2, AIRE and HOPE studies all being combined. This effect would be driven entirely by the outcomes of HOPE -high dose (10 mg) at night in highrisk CAD patients. Application of these results would have been appropriate in this set of patients only, and would have been extrapolated to hypertensive or other cardiovascular patients.
In a recent publication by Hansen, 44 the ACEIs were shown to demonstrate a similar clinical efficacy after myocardial infarction. The conclusion that there is a class effect is based on the treatment post MI in the acute setting and when used in comparable dosages. In the clinical data from the EUROPA 12 study, where 65% of patients had a history of MI, the use of 8 mg perindopril in this chronic setting demonstrated a reduction in the primary endpoint of major cardiac events, especially MI. The conclusion that 'the dosage used appears to influence clinical efficacy, and using appropriate dosage is thus important to achieve full benefits of treatment' is of paramount importance. Assuming a class effect of 'comparable dosages' is therefore flawed, as no dosage comparisons exist across the class of ACEIs. Therefore, only the proven clinically effective dosages of specific ACEIs should be used.
Conclusion
This overview of cardiovascular studies has clearly confirmed the hypothesis that trials utilising perindopril have consistently and convincingly demonstrated the clinical benefit of using this ACEI. The clinical outcomes from individual trials, as well as in a meta-analysis format, have proven the lack of a so-called class effect within the ACEI class. The point estimates of all the combined perindopril trials lie outside the CI of the overall estimate of all the ACEIs, indicating the excessive influence. It is evident that perindopril and, to a lesser extent, ramipril have good clinical outcomes, warranting their selection over any other ACEI.
Caution has to be used in the interpretation of the results, as many of the outcome studies, which met the search and methodological criteria of the meta-analysis, involved use of perindopril in varying dosages and in combination with a variety of other drugs. It is impossible to attribute all the benefits achieved solely to the effect of the ACEI. Used in combination with amlodipine or indapamide in different clinical settings demonstrated the proven benefit. This meta-analysis merely confirmed the effect that multiple therapies can achieve in various cardiovascular clinical settings. The use of perindopril alone or in combination with amlodipine and indapamide all contributed to the positive effects shown. The positive effects of indapamide and amlodipine individually may also have contributed to the positive results and would need to have a separate analysis to disprove.
Based on this meta-analysis, the assumption that a class effect exists for all ACEIs may not be the most correct option. To therefore knowingly recommend an ACEI that has no conclusive clinical outcomes data in any of the cardiovascular conditions discussed may need to be reviewed and reconsidered. 
Pfizer launches global regenerative medicine research unit
Pfizer recently announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity this provides to discover and develop a new generation of regenerative medicines for major medical needs.
Scientists at Pfizer Regenerative Medicine will explore the use of stem cells to develop future treatments that may prevent disability, repair failing organs and treat degenerative diseases. The ultimate goal will be to deliver new medicinal products that can pave the way for the use of cells as therapeutics. 'Pfizer Regenerative Medicine represents a great opportunity to focus world-class research in a field that holds considerable promise for biomedical science and for the treatment of many debilitating conditions such as diabetes and neurodegenerative disorders', said Dr Rod MacKenzie, head of worldwide research at Pfizer.
Dr Corey Goodman, president of Pfizer's Biotherapeutics and Bioinnovation Center, said, 'The formation of this new unit represents another key step forward in Pfizer's commitment to be at the forefront of new approaches in biotherapeutics and bio-innovation and to expand our research efforts and expertise into emerging areas of biomedical science, such as regenerative medicine, that have great potential for human health. ' The unit will be led by chief scientific officer, Dr Ruth McKernan, who said 'I'm very excited to lead this new research unit. While there is still a lot to understand about how stem cells can be used therapeutically, we believe it is one of the most promising areas of scientific research. ' Pfizer Regenerative Medicine will operate as one of Pfizer's new small, independent research units to help it foster a biotechnology culture and environment. A key component of the success of the units will be collaboration with leading academic, biotechnology and pharmaceutical partners around the world.
Pfizer Regenerative Medicine will be co-located in the biotechnology hubs of Cambridge, UK and Cambridge, Massachusetts in the United States. It is expected to expand to employ around 70 researchers. Scientists will operate in small, flexible teams, with the capability to make decisions quickly and effectively.
The Cambridge UK site is based at Granta Park and positions Pfizer in one of the strongest biotech regions in Europe. This unit will focus on neural and sensory disorders. The Cambridge, Massachusetts site is based at Pfizer's Research Technology Centre and will focus on endocrine and cardiac research.
